Using a muscle-building supplement to help repair nerve damage in multiple sclerosis
Muscle building supplement HMB for remyelination
This study is looking at whether a muscle-building supplement called HMB can help repair damaged nerve fibers in people with multiple sclerosis, which could lead to better movement and function.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rush University Medical Center NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10885153 on NIH RePORTER |
What this research studies
This research investigates the potential of β-hydroxy β-methylbutyrate (HMB), a muscle-building supplement, to promote the repair of damaged nerve fibers in multiple sclerosis (MS). The study will explore how HMB interacts with specific receptors in the brain that are involved in myelination, which is crucial for restoring nerve function. By testing HMB in animal models of MS, the research aims to determine if it can enhance the maturation of oligodendrocyte precursor cells and stimulate remyelination, potentially leading to improved motor function. Patients may benefit from insights gained about new therapeutic strategies for managing MS.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple sclerosis who are experiencing symptoms related to nerve damage.
Not a fit: Patients with other neurological conditions unrelated to demyelination may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance nerve repair in patients with multiple sclerosis.
How similar studies have performed: While the use of HMB in muscle building is well-known, its application for remyelination in MS is a novel approach that has not been extensively tested.
Where this research is happening
Chicago, United States
- Rush University Medical Center — Chicago, United States (Active)
Researchers
- Principal investigator: Pahan, Kalipada — Rush University Medical Center
- Study coordinator: Pahan, Kalipada
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.